Clinical Trial

Loratadine for the Prevention of G-CSF-related Bone Pain

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The research question for the current study is: Is loratadine more effective than placebo in preventing G-CSF-related bone pain during autologous hematopoetic stem cell transplant in patients with lymphoma or multiple myeloma? The hypothesis is that prophylaxis with loratadine will help prevent or reduce the severity of bone pain in this setting.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-06-13; most recent amendment 2026-02-03.
Status change: Not Yet Recruiting → Recruiting 2025-01-27
Trial Details
NCT Number NCT05421416
Lead Sponsor AHS Cancer Control Alberta
Conditions Stem Cell Transplant Complications
Enrollment 78 participants
Start Date 2024-11-28
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-05